Touchlight opens GMP production facility
Touchlight Genetics Ltd has established a GMP facility to support development of therapeutic products that incorporate the company’s revolutionary dbDNA™ vector technology. The facility will support clinical and commercial production for both in-house and partnered programs.
Touchlight has developed a revolutionary DNA vector known as doggybone™ DNA (dbDNA) which enables uniquely differentiated products across multiple advanced therapeutic modalities. dbDNA™ is enzymatically produced and can be manufactured at commercial scale DNA in a two-week process, disrupting the decades old fermentation approach.
The new facility comprises four suites, which collectively occupy a <50m2 foot print, and is capable of an annual production capacity of 100s of grams of GMP DNA. The facility is situated within the restored Hampton Water Works situated on the River Thames in West London.
Touchlight’s expansion comes at a time where there is dramatic growth in the area of advanced therapy, with hundreds of cell and gene therapy products currently in clinical trials and multiple landmark FDA approvals in 2017. Touchlight is partnering with leading biotechnology and pharmaceutical companies in this space in order to commercialise its technology platform.
Advanced medicines manufacturing is a growing focus in the UK, gaining significant investment from both private and public sources, including £270m through the Industrial Strategy Challenge Fund. Expansion of Touchlight’s DNA platform, that aims to underpin the success of advanced medicines, will directly support the mission to establish the UK life sciences sector as a world leader.
Following on from the opening of its R&D laboratory space in August 2017, the first phase of Touchlight’s site expansion is now complete. The expansion means that Touchlight is now ideally placed to enable a revolution in medicine with its cutting-edge DNA technology.
For further questions, please contact: email@example.com
- ENDS -
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone DNA” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Jonny Ohlson, CEO||Tim Watson|
|Robin Bodicoat, Head of Marketing||Agnes Stephens|
|E: firstname.lastname@example.org||E: email@example.com|
|T: +44 20 8481 9200||T: +44 20 7457 2020|